Literature DB >> 10195487

Incidence of aspiration pneumonia in intubated patients receiving activated charcoal.

J Moll1, W Kerns, C Tomaszewski, R Rose.   

Abstract

Several case reports and animal studies raise concerns over the risk of aspiration pneumonia when administering activated charcoal (AC) to intubated patients. Therefore, we sought to determine the incidence of aspiration pneumonia in intubated overdose patients who then received AC. We conducted a retrospective review from January 1994 to April 1997 of intubated patients who then received AC. Patients were transferred to, or primarily treated at, an 843-bed tertiary medical center with an annual emergency department volume of 100,000 patients. Objective evidence of infiltrate on chest radiograph during initial 48 h of hospitalization was used to determine the incidence of aspiration pneumonia. Patients with known preexisting pneumonia or with administration of AC before intubation were excluded. There were 64 patients identified. Fourteen were excluded for clinical aspiration before intubation, receiving activated charcoal before intubation, or abnormal immediate post-intubation chest radiographs. The remaining 50 patients, ages 1-64 years, 33% male, overdosing on a large variety of substances, required acute intubation and then received AC. Only two patients of these 50 (4%) with initial negative radiographs developed a new infiltrate after intubation and AC. Administration of AC to intubated overdose patients is associated with a low incidence of aspiration pneumonia.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10195487     DOI: 10.1016/s0736-4679(98)00192-9

Source DB:  PubMed          Journal:  J Emerg Med        ISSN: 0736-4679            Impact factor:   1.484


  8 in total

1.  The role of iNOS inhibitors on lung injury induced by gastrointestinal decontamination agents aspiration.

Authors:  Ahmet Güzel; Aygül Güzel; Mithat Günaydin; Hasan Alaçam; Osman Saliş; M Sükrü Paksu; Naci Murat; Ayhan Gacar; Tolga Güvenç
Journal:  J Mol Histol       Date:  2012-02-29       Impact factor: 2.611

2.  Lung disease 35 years after aspiration of activated charcoal in combination with pulmonary lymphangioleiomyomatosis. A histological and clinicopathological study with scanning electron microscopic evaluation and element analysis.

Authors:  M Huber; W Pohl; G Reinisch; J Attems; S Pescosta; F Lintner
Journal:  Virchows Arch       Date:  2006-06-15       Impact factor: 4.064

3.  Effect of Activated Charcoal on Rivaroxaban Complex Absorption.

Authors:  Edouard Ollier; Sophie Hodin; Julien Lanoiselée; Jean Escal; Sandrine Accassat; Elodie De Magalhaes; Thierry Basset; Laurent Bertoletti; Patrick Mismetti; Xavier Delavenne
Journal:  Clin Pharmacokinet       Date:  2017-07       Impact factor: 6.447

4.  Gastrointestinal decontamination in the acutely poisoned patient.

Authors:  Timothy E Albertson; Kelly P Owen; Mark E Sutter; Andrew L Chan
Journal:  Int J Emerg Med       Date:  2011-10-12

5.  Clinical Effects of Activated Charcoal Unavailability on Treatment Outcomes for Oral Drug Poisoned Patients.

Authors:  Sohyun Park; Hui Jai Lee; Jonghwan Shin; Kyoung Min You; Se Jong Lee; Euigi Jung
Journal:  Emerg Med Int       Date:  2018-10-03       Impact factor: 1.112

6.  Lung injury caused by aspiration of organophosphorus insecticide and gastric contents in pigs.

Authors:  Elspeth J Hulse; Richard E Clutton; Gordon Drummond; Adrian P Thompson; Edwin J R van Beek; Sionagh H Smith; Michael Eddleston
Journal:  Clin Toxicol (Phila)       Date:  2022-02-11       Impact factor: 3.738

Review 7.  Activated charcoal for acute poisoning: one toxicologist's journey.

Authors:  Kent R Olson
Journal:  J Med Toxicol       Date:  2010-06

Review 8.  Endotracheal Intubation in the Pharmaceutical-Poisoned Patient: a Narrative Review of the Literature.

Authors:  Glenn A Burket; B Zane Horowitz; Robert G Hendrickson; Gillian A Beauchamp
Journal:  J Med Toxicol       Date:  2020-05-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.